1182243-20-4

Upstream product

• 153034-86-7 2-chloro-4-iodopyridine 
• 1777-82-8 (2,4-dichlorophenyl)methanol 

Downstream Products

• 1260401-10-2 tert-Butyl 2-(4-(2,4-dichlorobenzyloxy)-2-oxopyridin-1(2H)-yl)-10-methyl-5,6,7,8,9,10-hexahydro-5,8-iminocyclohepta[4,5]pyrrolo[2,3-b]pyridine-11-carboxylate 
• 1260492-16-7 4-(2,4-dichlorobenzyloxy)-1-(6-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indol-8-yl)pyridin-2(1H)-one hydrochloride 
• 1260492-58-7 4-(2,4-dichlorobenzyloxy)-1-(10-methyl-5,6,7,8,9,10-hexahydropyrido[3',2':4,5]pyrrolo[3,2-c]azepin-2-yl)pyridin-2(1H)-one hydrochloride 
• 1382805-37-9 4-((2,4-dichlorophenyl)methoxy)-1-(9-methyl-5,7,8,9-tetrahydro-6H-pyrido[3',4':4,5]pyrrolo[2,3-b]pyridin-2-yl)pyridin-2(1H)-one 

Relevant academic research and scientific papers

TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF

The present invention relates to tetrahydro-azacarboline derivatives of formula (I): having the substituents as described herein which are melanin-concentrating hormone (MCH-1) receptor antagonists. The present invention also relates to pharmaceutical com

AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are als